FloBio
FloBio LLC is pioneering a novel fluidic-based diagnostic platform technology that assesses bleeding and thrombotic risk at the point-of-care, with clinical applications being developed for emergency critical care patients. The company aims to transform emergency critical care patient management by providing rapid, actionable information to clinicians, enabling optimal decision-making and cost-effective management of blood clotting abnormalities and serious bleeding. With a focus on innovative hemostasis testing, FloBio develops advanced microfluidic devices and assays to improve diagnosis and treatment of bleeding risks, especially related to anticoagulant drugs like DOACs.
Industries
Nr. of Employees
small (1-50)
FloBio
3401 Grays Ferry Avenue, Building 450, Philadelphia, PA 19146
Patents
System and method for coagulation and platelet function related data collection and analysis
US-12578350-B2
View Details
System and method for coagulation and platelet function related data collection and analysis
US-12578350-B2
View DetailsProducts
Point-of-care functional hemostasis diagnostic platform
Integrated tabletop analyzer, disposable multi-channel microfluidic cartridges, and proprietary software for rapid functional assessment of clotting and anticoagulant status from whole blood.
Rapid DOAC detection assay (in development)
A functional assay designed to detect presence, classify, and estimate levels of direct oral anticoagulants from whole blood to inform reversal and treatment decisions.
Point-of-care functional hemostasis diagnostic platform
Integrated tabletop analyzer, disposable multi-channel microfluidic cartridges, and proprietary software for rapid functional assessment of clotting and anticoagulant status from whole blood.
Rapid DOAC detection assay (in development)
A functional assay designed to detect presence, classify, and estimate levels of direct oral anticoagulants from whole blood to inform reversal and treatment decisions.
Services
Co-development and clinical feedback integration for point-of-care hemostasis assays with hospital and clinician partners.
Co-development and clinical feedback integration for point-of-care hemostasis assays with hospital and clinician partners.
Expertise Areas
- Point-of-care hemostasis diagnostics
- Microfluidic device development
- Whole-blood functional assays under flow
- Anticoagulant (DOAC) assay development
Key Technologies
- Microfluidics
- Flow-based hemodynamic assays
- Fluorescence-based detection
- Disposable single-use microfluidic chips
News & Updates
FloBio was recognized as a semi-finalist in the 2022 AACC Disruptive Technology Competition and participated in the 2022 AACC Annual Scientific Meeting + Clinical Lab Expo in Chicago, IL from July 24-28.
FloBio announced that the FDA granted Breakthrough Device Designation for its rapid bleeding risk diagnostic test, which determines blood clotting status and whether a patient is on blood thinners called DOACs. This test aims to help emergency and critical care clinicians make informed treatment decisions to reduce serious bleeding complications.
FloBio received Breakthrough Device Designation from the FDA for its bleeding risk diagnostic test, recognizing its potential to provide more effective diagnosis and treatment of life-threatening conditions.
FloBio was recognized as a semi-finalist in the 2022 AACC Disruptive Technology Competition and participated in the 2022 AACC Annual Scientific Meeting + Clinical Lab Expo in Chicago, IL from July 24-28.
FloBio announced that the FDA granted Breakthrough Device Designation for its rapid bleeding risk diagnostic test, which determines blood clotting status and whether a patient is on blood thinners called DOACs. This test aims to help emergency and critical care clinicians make informed treatment decisions to reduce serious bleeding complications.
FloBio received Breakthrough Device Designation from the FDA for its bleeding risk diagnostic test, recognizing its potential to provide more effective diagnosis and treatment of life-threatening conditions.